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Abstract
The prognostic value of two antibodies targeting citrullinated
antigens, anti-Sa and anti-cyclic citrullinated peptide (CCP),
present at inclusion, was evaluated prospectively in a cohort of
165 consecutive patients with recent-onset or early polyarthritis
(EPA) followed for up to 30 months. Patients were treated
according to current Good Clinical Practice standards.
Predefined outcomes were severe arthritis and persistent
arthritis. At inclusion, a median of 3 months after disease onset,
133 (81%) patients fulfilled at least four American College of
Rheumatology criteria for rheumatoid arthritis and 30 (18%) had
erosive changes on radiographs of hands and feet. Disease-
modifying anti-rheumatic drugs were used in close to 80% of the
patients at 30 months. Joint damage increased linearly over
time, whereas disease activity declined markedly and remained
low at each follow-up. Autoantibodies were identified in 76
(46%) patients: rheumatoid factor (RF) in 68 (41%), anti-CCP
in 53 (33%), and anti-Sa in 46 (28%). All three antibodies were
correlated, but anti-Sa antibodies best predicted severity at 18
and 30 months. RF and anti-CCP performed less well. For both
outcomes, anti-Sa alone performed better than any combination
of antibodies. The presence of any autoantibody identified about
50 to 60% of the patients with poor outcomes. In multivariate
analysis, anti-Sa (odds ratio (OR) 8.83), the presence of
erosions at inclusion (OR 3.47) and increasing age (OR 1.06/
year) were significantly associated with severity, whereas RF
and anti-CCP were not significant predictors. Persistent arthritis
was present in up to 84% of patients; autoantibodies were
specific but poorly sensitive predictors of this outcome. We
conclude that assays for antibodies against citrullinated
antigens differ in their ability to predict poorer outcomes in
patients with EPA. In our EPA cohort treated in accordance with
current standards, detection of anti-Sa but not of RF or anti-
CCP antibodies, in combination with clinical and radiological
variables present at the first encounter, allowed the identification
of a subgroup of EPA patients suffering more rapid and more
severe joint damage over 30 months.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory arthritis
that frequently starts at the peak of productive life and is a
major cause of invalidity, morbidity, and premature mortality
[1]. RA is characterized by an early inflammatory stage that is
frequently responsive to disease-modifying anti-rheumaticR592
ACR = American College of Rheumatology; BSA = bovine serum albumin; CCP = cyclic citrullinated peptide; CHUS = Centre hospitalier universitaire 
de Sherbrooke; CRP = C-reactive protein; DAS28-3 = Disease Activity Score using 28 joints and 3 variables (tender and swollen joint counts and 
CRP); DMARD = disease-modifying anti-rheumatic drug; ELISA = enzyme-linked immunosorbent assay; EPA = early (or recent-onset) polyarthritis; 
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R593drugs (DMARDs) [2]. At a temporally undefined later stage,
the RA process evolves towards pannus formation responsi-
ble for the joint destruction. Once established, pannus may
progress on its own, independently of the apparent response
to DMARDs. No available treatment can reverse significant
joint damage. These observations gave rise to the notion of a
therapeutic 'window of opportunity' during which the rheuma-
toid process would be more likely to be stopped or retarded
[2,3]. This notion is supported by the fact that aggressive
treatment of early RA decreases both mortality and long-term
invalidity and can increase the rate of long-term remission [4-
8]. The identification, early into disease, of those patients likely
to evolve rapidly to pannus formation and destructive/disa-
bling arthritis would allow the most cost-effective use of
expensive treatments and, reciprocally, would minimize unnec-
essary exposure of spontaneously remitting patients to the
risks of aggressive treatments.
Sufficiently specific and sensitive prognostic markers that
could be used with confidence in the individual patient with
early or recent-onset polyarthritis (EPA) and recent-onset RA
are still lacking [9-11]. For example, even within patients fulfill-
ing the 1987 revised classification criteria for RA of the Amer-
ican College of Rheumatology (ACR; formerly the American
Rheumatism Association) [12], chronic arthritis presents wide
variations in response to treatments, degree of inflammation,
and potential for joint destruction and functional impairment
[13]. Classification criteria have even more limited value in pre-
dicting outcomes of patients with recent-onset polyarthritis
[14]. A second challenge is the frequent occurrence of spon-
taneous remission in early polyarthritis present for up to 3 to 6
months. This relatively benign evolution is well documented,
both in population-based studies [15,16] and in cohort studies
of patients with polyarthritis of recent onset [17,18]. As a con-
sequence, clinicians frequently adopt a watch-and-see atti-
tude with patients during the first months of disease, delaying
treatment with irreversible detrimental consequences [6].
Recently, antibodies targeting determinants resulting from the
deimination of peptidylarginine to peptidylcitrulline residues
have been described in the serum of patients with RA [19].
These include antibodies targeting cyclic citrullinated peptide
(CCP) [20] and antibodies targeting in vivo citrullinated pro-
teins, such as anti-keratin antibodies, antiperinuclear factor,
anti-citrullinated (pro)filaggrin and anti-Sa/citrullinated vimen-
tin [21,22]. The specificity of these antibodies for established
RA, either rheumatoid factor (RF)-positive or RF-negative, and
their presence in patient sera in the preclinical and early clini-
cal phases of disease have been documented [23,24]. The
serum of most patients with diseases other than RA, either RF-
positive or RF-negative, does not contain antibodies against
citrullinated peptides or proteins [20]. Assays to detect these
anti-citrullinated peptides/proteins might therefore be useful to
predict poor outcomes in patients with early polyarthritis [25-
27], although their added value relative to RF was found to be
modest or even controversial [28-31].
The purpose of our study was to assess the prognostic role of
anti-Sa and of anti-CCP antibodies, relative to RF, in patients
with polyarthritis evaluated and treated early after the onset of
disease, irrespective of the fulfillment or not of diagnostic cri-
teria for a specific disease entity. We now present an analysis
of our cohort at 30 months of follow-up.
Methods
Patients
Consecutive adult patients with synovitis affecting at least
three joints for at least 1 month and less than 12 months and
evaluated at the Centre hospitalier universitaire de Sherbrooke
(CHUS) were asked to participate to the study. The CHUS is
the single regional rheumatology referral center for about
400,000 people, and is the site of practice of six of the seven
rheumatologists in the area. Patients with bacterial or crystal-
induced arthritis, patients with a defined connective tissue dis-
ease (looked for both clinically and by autoantibody testing
[32]), patients with systemic vasculitis according to ACR cri-
teria [33], and those who declined or were unable to consent
were excluded. Failure to fulfill ACR criteria for RA [12], the
presence of skin or nail lesions typical of psoriasis or psoriasis-
like lesions, inflammatory bowel disease, clinical features sug-
gestive of a spondylarthropathy [34], signs or symptoms sug-
gestive of a connective tissue disease without fulfillment of
specific ACR criteria, and the presence of positive HLA-B27
were not reasons for exclusion. Most of the included patients
were regularly followed by rheumatologists and treated with
the current approach of early and intensive treatment with
DMARDs [2,35]. Patients, rheumatologists, coordinating
nurses and treating physicians remained blinded to the
patients' HLA-DR, anti-CCP and anti-Sa status. Serum and
DNA materials were coded to ensure confidentiality and blind-
ing of investigators. All patients gave their informed consent
and the ethics review board of the CHUS approved the study.
Disease variables
A rheumatologist completed a structured physical examina-
tion, including 68 tender and 66 swollen-joint count assess-
ments and identification of extra-articular manifestations. A
trained nurse coordinator performed a structured interview at
the inclusion visit and at each of the follow-up visits scheduled
at 18, 30, 42 and 60 months after the onset of inflammatory
arthritis. The time of onset of arthritis was assumed to be the
month during which the patient indicated that joint symptoms/
signs had appeared or, in patients with previous musculoskel-
etal complaints (such as osteoarthritis), at the time that the
signs or symptoms of inflammatory arthritis appeared, additive
to the previous signs and symptoms. Scheduling the follow-up
evaluations relative to the onset of symptoms rather than to the
establishment of diagnosis sought to ensure that the cohort
was more homogeneous in disease duration on follow-up.
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len joint counts, duration of morning stiffness, use of DMARDs
and corticosteroids at and between each visit, modified Health
Assessment Questionnaire (M-HAQ) [36], erythrocyte sedi-
mentation rate (according to the Wintrobe method), serum C-
reactive protein (CRP; lower limit of detection 3.0 mg/L, upper
normal limit 8.0 mg/L), serum RF (latex agglutination, RapiTex
RF; Dade Behring Inc, Newark, DE, USA; threshold for posi-
tive results set at 40 IU/ml on the basis of clinical experience
and confirmed by its optimal prognostic value), genomic typing
of the HLA-DR (see below), measure of anti-Sa antibodies
(see below) and anti-CCP antibodies (QuantaLite™; Inova
Diagnostics, San Diego, CA, USA; in accordance with the
manufacturer's recommendations). Standardized radiographs
of the hands and feet were obtained at inclusion and at each
scheduled assessment. Joint space narrowing and erosions
were scored by the Sharp–van der Heijde (SvH) method, with
a maximum score of 448 [37]. All radiographs were read in
pairs in a known time sequence by a trained reviewer who was
blinded to the corresponding clinical information. The smallest
detectable difference was shown to be 5 units; this was
assumed to be identical to the minimal clinically important dif-
ference [38,39]. Functional status was determined at each
visit by using validated French-Canadian or English versions of
the M-HAQ with a range of 0 to 3 (good functional status to
maximal disablement). Disease Activity Score using 28 joints
and 3 variables (tender and swollen joint counts and CRP;
DAS28-3) was calculated with the appropriate formulas http:/
/www.das-score.nl [40]. A DAS28-3 score below 2.6 defined
clinical remission [41,42], whereas a score above 3.2 indi-
cated more than mild disease.
Predefined outcomes
Persistent arthritis was defined as the presence of at least one
joint with synovitis and/or the current use of DMARDs or at
least 10 mg of prednisone equivalent per day [25]. Fulfillment
of RA criteria required at least four ACR criteria for RA. Sever-
ity required an M-HAQ score of at least 1.0 and/or belonging
to the upper third of the SvH radiological score.
Genomic PCR typing at the HLA-DR and HLA-DQ
Genomic DNA was extracted from leukocytes present in 2.5
ml of EDTA-treated whole blood using Wizard DNA extraction
kit (Promega Corporation, Madison, WI, USA), then stored at
4°C. Genomic typing was performed by using PCR with
sequence-specific primers specific for HLA class II molecules
[43,44]. Primer sets for low-resolution typing of HLA-DR and
HLA-DQ antigens, and high-resolution typing of DRB1*01,
DRB1*04, DRB1*14 and DQB1 loci were from Pel-Freez Clin-
ical Systems (Brown Deer, WI, USA). After amplification, PCR
products (10 µl) were resolved in a 2% agarose gel containing
ethidium bromide and detected by ultraviolet transillumination.
Amplification patterns were interpreted in accordance with the
manufacturer's instructions. HLA-DRB1 alleles encoding the
amino acid sequences QRRAA (DRB1*0101, DRB1*0102,
DRB1*0105, DRB1*0404, DRB1*0405 and DRB1*0408),
QKRAA (DRB1*0401 and DRB1*0409) and RRRAA
(DRB1*1001) were considered to encode the shared epitope.
Anti-Sa/citrullinated vimentin
The Sa antigen was first detected in human spleen/placenta
extracts by western blotting (WB) [21] and subsequently iden-
tified as citrullinated vimentin [22]. Most citrullinated arginine-
rich proteins are adequate but not absolutely equivalent rea-
gents for the detection of antibodies against citrullinated
epitopes, as discussed in [22]. Because access to human tis-
sues and consistent extraction of the Sa antigen from tissues
proved problematic, and commercial human vimentin is very
expensive, we developed standardized and less expensive
assays. We screened several cell lines and identified the ECV
304 endothelial cell line as rich in both vimentin and peptidy-
larginine deiminases (PADIs). Auto-citrullinated extracts from
ECV 304 cells (see below) paralleled human placenta extracts
for anti-Sa detection in WB. We then used this ECV 304-
based WB assay to monitor the performance of an in-house
enzyme-linked immunosorbent assay (ELISA), designed with
in vitro citrullinated bovine myelin basic protein (MBP). MBP
and vimentin have similarly high proportions of arginine. Most
positive results in MBP-ELISA correlated with positive anti-Sa
results on the original WB method using human placenta.
Anti-Sa WB assay
ECV 304 cells were cultured at 37°C under 5% CO2 in IMDM
(Sigma Chemical Co., St Louis, MO, USA) enriched with 10%
fetal bovine serum containing 3.024 g/L sodium bicarbonate
(pH 7.2). At confluence, cells were trypsinized, washed, incu-
bated for 5 min on ice in 1 ml of buffer containing 40 mM Tris-
HCl pH 7.5, 1 mM EDTA pH 8.0, 0.150 NaCl, and mechani-
cally detached. The resultant cell pellet was submitted to three
freeze-thaw cycles, and the supernatant was clarified by cen-
trifugation. The concentration of protein was measured by the
Bradford assay (Bio-Rad), and the extracts were stored at -
80°C. In preparation for WB, the extracts (2.5 µg per tested
serum) were auto-citrullinated for 3 hours at 37°C in 50 mM
citrullination buffer (Tris-HCl pH 7.5, 10 mM CaCl2, 10 mM
dithiothreitol). The reaction was stopped with EDTA (100 mM
final concentration). An equal volume of 2× WB loading buffer
was added to the citrullinated extract for long-term storage in
aliquots at -20°C. WB was performed as described [21], with
ECV 304 native and citrullinated extracts being run in parallel.
Sera were tested in duplicate at a dilution of 1:100 and results
are expressed as either positive or negative.
Anti-Sa ELISA
Bovine MBP (Sigma) was citrullinated in vitro by incubation for
3 hours at 37°C in citrullination buffer containing 0.2 U rabbit
PADI 2 (Sigma) per µg of MBP. Microtiter plates (96 wells;
Nunc Maxisorp, WWR International Ltd., Mississauga, ON,
Canada) were coated overnight at 4°C with native or citrulli-
nated bovine MBP at 1 µg per well. The plates were blocked
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ing 1% (w/v) BSA, then washed three times with PBS contain-
ing 0.05% Tween 20 (PBST). The plates were incubated for 1
hour at room temperature with 100 µl per well of human serum
diluted 1:300 in PBS containing 1% (w/v) BSA (PBS-BSA),
and then washed three times with PBST. Bound human IgG
was detected with a goat anti-human IgG, alkaline phos-
phatase-labeled conjugate (Jackson ImmunoResearch Labo-
ratories Inc., West Grove, PA, USA) diluted 1:1000 in PBS-
BSA. The reaction was detected with 1 mg/ml p-nitrophenyl
phosphate (Sigma) in substrate buffer (10% diethanolamine,
0.5 mM MgCl2, pH 9.8) for 20 min at room temperature. The
absorbance, A, was read at 405 nm. Each sample was run in
duplicate and in parallel on native MBP (N), on citrullinated
MBP (C), and on BSA (B). Results were given by the equation
A405 = AC – AN. A positive test was defined as A405 > 0.2. A
known positive control serum was used on each plate for rea-
gent quality control. The BSA control was used to detect spu-
rious intrinsic individual serum stickiness for which some RA
sera are notorious. When a serum gave high A405 when used
on BSA alone, a positive anti-Sa ELISA result had to be con-
firmed on WB to be reported as positive. All the anti-Sa assays
described here were developed and performed on coded sera
at the McGill University Autoimmune Research Laboratory.
Statistical analysis
The principal independent variables were anti-Sa (MBP-
ELISA), anti-CCP (positive if more than 20 U/ml), and RF (pos-
itive if at least 40 IU/ml) antibodies. The degree of association
between anti-Sa and anti-CCP assays was measured by using
the phi coefficient. Sensitivity, specificity and positive likeli-
hood ratio (LR) were calculated for each of the three outcome
measures at 18 and 30 months into disease and for each of
the 13 following putative prognostic markers present at the
inclusion visit: anti-Sa, anti-CCP, RF, sex, age (in years), dura-
tion of disease (in months), duration of morning stiffness (pos-
itive when at least 1 hour), symmetry of joint swelling, number
of joints with synovitis, M-HAQ score (positive when at least
1.0), RA-associated HLA-DRB1 alleles ('shared epitope'),
CRP levels (positive when higher than 8.0 mg/L), and an ero-
sion component of the SvH score of at least 5. The predictive
ability of anti-Sa, anti-CCP, and RF in the early identification of
patients with each outcome was also studied by using the area
under a receiver operating characteristics curve. Confidence
intervals were calculated for these estimates. After these esti-
mations, a logistic regression approach was used to estimate
the independent contribution of RF, anti-Sa, and anti-CCP
present at inclusion to predict the development of outcomes
at 30 months. Each autoantibody was evaluated separately
Table 1
Baseline characteristics of the study population (n = 165)
Characteristic Value
No. female (%) 95 (57.6)
Median age, years (range) 58.8 (19–85)
Median duration of symptoms, months (range) 3 (1–12)
No. with disease duration of 3 months or less (%) 87 (52.7)
Median number of joints with synovitis (range) 10 (3–58)
No. fulfilling at least four ACR criteria for RA (%) 133 (80.6)
Mean M-HAQ score (range) 0.93 (0–2.75)
No. with M-HAQ score ≥ 1.0 (%) 77 (47.0)
Median DAS28-3 score (range) 5.01 (2.09–7.85)
No. with RF ≥ 40 IU/mL (%) 68 (41.2)
No. with anti-CCP ≥ 20 U/mL; positive (%) 53 (33.1)
No. with positive anti-Sa antibodies (%) 46 (28.0)
No. with CRP ≥ 8.0 mg/L (%) 119 (72.6)
No. with at least one HLA-DR 'shared epitope' (%) 77 (47.0)
No. with two HLA-DR 'shared epitopes' (%) 22 (13.4)
Median SvH score (range) 4 (0–54)
No. with total SvH score ≥ 10 (%) 31 (18.8)
No. with erosion SvH score ≥ 5 (%) 30 (18.2)
ACR, American College of Rheumatology; CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS28-3, Disease Activity Score using 28 
joints and 3 variables (tender and swollen joint counts and C-reactive protein); M-HAQ, modified Health Assessment Questionnaire; RA, 
rheumatoid arthritis; RF, rheumatoid factor; SvH, Sharp–van der Heijde.
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model of prognostic factors listed above. A final statistical
model was constructed with the stepwise logistic regression
approach. By using the variables included in the final model,
with and without the inclusion of anti-Sa and anti-CCP anti-
bodies, the odds ratio (OR) was calculated to estimate the
contribution of each marker adjusted for the other markers in
the prediction of the severity outcome.
Results
Patient characteristics at study entry
Up to May 2004, 260 patients agreed to participate and were
included. Eleven additional patients declined to participate or
had very incomplete inclusion data and were excluded. At this
time, 165 patients had reached the 30-month evaluation mark.
Of these patients,5 had died and 11 failed to come to their
scheduled appointment. We therefore report on the 149
patients (retention rate 90.3%) with a complete 30-month
assessment.
The baseline characteristics at entry of the 165 patients are
summarized in Table 1. The 16 patients who died or who were
lost to follow-up did not differ significantly on any of the inclu-
sion variables from the 149 who were followed up (data not
shown). Men (42.4% of our patients) were slightly older than
women (61.7 versus 58.0 years). These patients had a dis-
ease of short duration (mean 4.4 months, median 3 months).
Nevertheless, at inclusion, 80.6% of the patients already ful-
filled at least four ACR criteria for RA, 47% were functionally
disabled (M-HAQ at least 1.0), and 18% had significant ero-
sive changes (SvH erosion score of 5 or more).
The prevalence of autoantibodies was low. RF was found in 68
(41.2%) patients, anti-CCP in 53 (33.1%), and anti-Sa in 46
(28.0%). As reported previously [20,29], the presence of anti-
CCP, RF, and anti-Sa was moderately to highly correlated
(Kendall's tau-b > 0.6 for all comparisons). A total of 76 sera
contained either one of RF, anti-CCP, or anti-Sa antibodies,
and 35 sera contained all three. RF and anti-CCP co-existed
in 46 patients, RF and anti-Sa in 41, and anti-Sa and anti-CCP
in 39. This means that, despite a good correlation between
assays, 13 (19.1%) of the 68 sera with RF did not contain anti-
bodies against citrullinated antigens, CCP or Sa. Interestingly,
the degree of association between anti-Sa and anti-CCP (titer
higher than 21 U/ml; phi coefficient 0.6881) was very similar
to the degree of association between anti-Sa and high titer
anti-CCP only (titer higher than 100 U/ml; phi coefficient
0.6339). This absence of variation of the degree of association
with increasing titers suggests that anti-Sa and anti-CCP
assays differ qualitatively. The shared epitope at the HLA
Table 2
Clinical assessments and outcomes at inclusion and during follow-up
Measure Inclusion (n = 165) 18 months (n = 156) 30 months (n = 149)
Mean M-HAQ score (median) 0.93 ± 0.64 (0.875) 0.42 ± 0.50 (0.25) 0.35 ± 0.41 (0.25)
No. with M-HAQ ≥ 1.0 (%) 76 (46.1) 18 (11.6%) 17 (11.5%)
Mean DAS28-3 score (median) 5.01 ± 1.27 (4.94) 2.94 ± 1.26 (2.66) 2.81 ± 1.06 (2.46)
No. with DAS28-3 < 2.6 (%) 5 (3.0) 76 (48.7) 82 (55.0)
Mean swollen joint count (median) 12.55 ± 9.57 (10) 2.83 ± 5.51 (0) 2.04 ± 3.64 (0)
Number without synovitis (%) n.a. 72 (46.2) 82 (55.0)
Number with persistent arthritis (%) n.a. 137 (87.8) 125 (83.9)
No. fulfilling criteria for RA (%) 133 (80.6) 36 (23.1) 28 (18.8)
No. with severe arthritis (%) 106 (64.2) 65 (41.7) 56 (37.8)
Mean total SvH score (median) 6.05 ± 8.38 (4) 11.34 ± 13.82 (7) 15.76 ± 18.38 (10)
Mean erosion SvH score (median) 3.02 ± 4.99 (1) 6.94 ± 9.37 (4) 10.31 ± 13.14 (7)
Upper third of the total SvH score >5 >10 >15
No. on DMARDs (%)
Total 31 (18.8) 120 (76.9) 116 (77.9)
RF-positive 13/68 (19.1) 60/63 (95.2) 60/61 (98.4)
Anti-CCP-positive 10/53 (18.9) 49/52 (94.2) 50/51 (98.0)
Anti-Sa-positive 6/46 (13.0) 43/45 (95.6) 44/44 (100.0)
CCP, cyclic citrullinated peptide; DAS28-3, Disease Activity Score using 28 joints and 3 variables (tender and swollen joint counts and C-reactive 
protein); M-HAQ, modified Health Assessment Questionnaire; n.a., not applicable; RF, rheumatoid factor; SvH, Sharp–van der Heijde. Where 
errors are shown, results are means ± SD.
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(47%) of those fulfilling criteria for RA at inclusion. Twenty-two
patients (13.4%) carried two shared epitope alleles.
Evolution of the clinical status from inclusion to the 18-
month and 30-month evaluations
Upon follow-up, the clinical status of the patients improved
markedly (Table 2). The DAS28-3, the M-HAQ, and the swol-
len joint counts all significantly decreased. Despite this appar-
ent control of clinical disease activity relative to inclusion, the
radiological SvH score increased steadily at each follow-up,
both in the total score and in its erosion component (Fig. 1). A
high proportion (77.9%) of patients was still being actively
treated with DMARDs at 30 months. Interestingly, despite
blinding of their treating physicians, the patients with anti-Sa
and anti-CCP were treated as intensively as RF-positive
patients. Most treated patients were on 15 to 25 mg/week
methotrexate, with about two-thirds (77 of 116) on combina-
tion therapies. Despite this liberal use of DMARDs, nine
patients with at least one swollen joint were not being treated
with DMARDs at 30 months. Those untreated patients repre-
sented 13% of patients with synovitis at this follow-up.
According to our definition (see above and similar to that in
[25]), persistent arthritis was said to be present when swelling
was detectable in at least one joint and/or when at least one
DMARD or at least a moderate dose of corticosteroids was
used at the time of follow-up. Thus, 88% and 84% of the
patients were considered as having persistent arthritis at 18
and 30 months, indicating that long-term spontaneous remis-
sion was unusual in our EPA cohort, as reported previously in
[45]. Close to half (namely 53 of 137 and 58 of 125, at 18 and
30 months, respectively) of the patients labeled 'persistent
arthritis' had no swollen joints at each follow-up. The good clin-
ical control of disease in our patients was also evident when
using the DAS28-3 score: 76 (48.7%) had a score of less
than 2.6 ('remission' [41,42]) at 18 months, and 82 (55.0%)
at 30 months. Thus, more than half of our initial cohort was in
remission as defined by DAS28-3 at 30 months, arguably the
highest proportion of remission in a cohort of patients with
EPA [6].
Severe arthritis was present in 56 (38%) patients at 30
months. Our inclusive definition of severity (upper third of SvH
score and/or M-HAQ ≥ 1.0) did not make any a priori assump-
tion about the rate of damage progression in our patients, as
this should be highly dependent on the characteristics of the
patients included and (possibly) the treatments used. The
threshold for the upper third of SvH score was calculated as a
total score of more than 10 at 18 months and more than 15 at
30 months, that is, about 2% and 3.5%, respectively, of the
maximal SvH score. Not surprisingly, functional impairment
was the criterion most determinant for selection in the group
with severe disease at inclusion, whereas radiological damage
became the major reason for selection during follow-up.
Only 28 (18.79%) patients still fulfilled at least four ACR crite-
ria for RA at 30 months. At inclusion or on follow-up, 20
patients fulfilled criteria for inflammatory rheumatic diseases
other than RA: 13 had arthritis associated with skin psoriasis
(present at inclusion in 12), 3 had benign sarcoid arthritis, 3
had spondylarthropathy, and 1 had scleroderma. Autoantibod-
ies were present at low frequency in these patients: RF in four,
anti-Sa in two, and anti-CCP in one. At each of the follow-up
visits, more than two-thirds of the patients (namely 101 of 156
and 101 of 149 at 18 and 30 months, respectively) did not ful-
fill criteria for a specific diagnosis and might thus be classified
as undifferentiated arthritis.
Autoantibodies as predictors of poor outcomes
We first determined the sensitivity, specificity and positive LR
of the presence of autoantibodies at onset as prognostic mark-
ers for predefined outcomes (Table 3). Anti-Sa stood out as
the single moderately good marker (positive LR 2.16) to pre-
dict the development of severe arthritis. In this regard, anti-
CCP (positive LR 1.38) and RF (positive LR 1.50) gave simi-
larly poor results. It is remarkable that, despite the lower prev-
alence of anti-Sa in our cohort, its sensitivity for the severity
Figure 1
Total Sharp–van der Heijde (SvH) score at inclusion and at 18 and 30 months
months. Mean values and 95% confidence limits are illustrated. The 
four curves represent groups of patients at inclusion who had an ero-
sion SvH score of at least 5 and positive anti-Sa (15, 14, and 14 
patients at each visit) (squares), an erosion SvH score of at least 5 and 
negative anti-Sa (15, 13, and 13 patients at each visit) (circles), an ero-
sion SvH score of 4 or less and positive anti-Sa (32, 30, and 30 
patients at each visit) (triangles), and an erosion SvH score of 4 or less 
and negative anti-Sa (103, 97, and 92 patients at each visit) 
(diamonds).
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R598outcome was very similar to that of RF and anti-CCP. Any com-
bination of RF and/or anti-CCP with anti-Sa was no better than
anti-Sa alone in predicting severe outcomes. In contrast, anti-
bodies present at inclusion were specific but poorly sensitive
predictors of persistent arthritis at 30 months. Owing to our
inclusive a priori definition (see above and similar to that in
[25]), persistent arthritis was observed in 84% of the patients
at 30 months. Thus, despite their strong positive LR, antibod-
ies were not clinically helpful in predicting persistence in our
cohort at the 30-month evaluation mark. We therefore looked
at alternative definitions of persistent arthritis, such as non-
remission defined by DAS28 (namely presenting a DAS28-3
score of at least 2.6). Non-remission defined by DAS28-3 was
present in 45% of our aggressively DMARD-treated patients
at the 30-month evaluation. None of the three antibodies was
correlated with non-remission defined by DAS-28 (data not
shown), suggesting that the presence of antibodies does not
correlate with a poorer response to (conventional) DMARD
treatments. Persistence defined as non-remission defined by
DAS28-3 was therefore not used further. Finally, no autoanti-
body correlated with the fulfillment of RA criteria, mostly
because of poor specificity. The best serological markers for
the fulfillment of criteria for RA at 30 months were RF and anti-
Sa, which gave low but very similar positive LR values (1.53
and 1.54, respectively). This result probably reflects the damp-
ening impact of treatment on the clinical activity of arthritis.
In all three evaluated outcomes, RF had a higher sensitivity
than anti-Sa, whereas anti-Sa had a higher specificity than RF
(except for the fulfillment of RA criteria). Anti-CCP also had a
slightly better specificity than RF for predefined outcomes.
However, despite their high specificity for established RA,
anti-CCP antibodies performed poorly. The same differences
between anti-CCP and anti-Sa antibodies, although present,
were less marked at the 18-month evaluation (data not
shown). As noted above, anti-Sa alone performed better than
any combination of antibodies in predicting severity. The con-
clusions were not significantly different when the analysis was
restricted to patients fulfilling RA criteria at inclusion (data not
shown). As noted in Table 2, specific avoidance of DMARDs
in anti-Sa patients could be discarded as a possible explana-
tion for their more rapid radiographic deterioration, because
these patients were as intensively treated as patients with RF.
Multivariate prognostic models of severity
As illustrated in the multiple regression model for severity
(Table 4, model A), anti-Sa (OR 8.832) clearly outperformed
RF and anti-CCP. Indeed, the presence of anti-Sa conferred
an even higher OR than erosion SvH abnormalities (OR
3.472), and was the most powerful independent predictive
variable for the severity outcome. The OR of anti-Sa increased
after adjustment for all other included variables. Although anti-
Sa was the best individual marker for severity, a combination
of anti-Sa, an SvH erosion score of at least 5 and increasing
age best explained severe disease development. Worth noting
is the absence of a HLA-DR 'shared-epitope', disability
defined by M-HAQ, and the fulfillment of ACR criteria for RA
from the short list of variables present at inclusion that were
predictive of the predefined severe outcome.
However, anti-Sa antibodies are not widely available yet, and
their presence in the model might have wiped out significant
associations of RF and/or anti-CCP with severe arthritis. After
the removal of anti-Sa from the analysis, neither RF nor anti-
CCP was significantly predictive of severe arthritis (Table 4,
model B). At that time, we suspected some heterogeneity
among patients with anti-CCP. Receiver operating character-
istics curves indicated that a cut-off of 61 U/ml of anti-CCP,
Table 3
Autoantibodies as prognostic markers of poor outcomes
Autoantibody Measure Outcomes at 30 months
Persistence RA criteria Severity
RF Sensitivity 47.2 57.1 55.4
Specificity 91.7 62.8 63.0
Positive LR 5.69 1.53 1.50
Anti-Sa Sensitivity 34.4 39.3 44.6
Specificity 95.8 72.7 79.3
Positive LR 8.26 1.44 2.16
Anti-CCP Sensitivity 39.2 39.3 42.9
Specificity 91.7 66.9 70.7
Positive LR 4.70 1.19 1.46
Combinations of antibodies (rheumatoid factor (RF) and/or anti-Sa and/or anti-cyclic citrullinated peptide (anti-CCP)) are not shown, because 
none brought any improvement over the detection of anti-Sa alone. LR, likelihood ratio; RA, rheumatoid arthritis.
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R599rather than 21 U/ml, would yield an improved positive LR of
2.01 for the severity outcome (data not shown). Similarly, after
deletion of anti-Sa results and restriction to titers of anti-CCP
higher than 60 U/ml, the predictive value of anti-CCP
improved but remained below that of RF; neither reached a
statistically significant level (Table 4, model C).
Finally, we tested the interaction of erosion SvH score and
anti-Sa, the two major initial predictors of severe arthritis on
the development of joint damage (Fig. 1). Each of the two pre-
dictors influenced the 30-month SvH score, with significant
erosive damage at inclusion being the most determinant for
the rate of progression of radiological damage. In patients in
whom erosion SvH scores were abnormal at inclusion, the rate
of yearly increase of the total SvH score was about 10 units.
This rate was about 4 units/year in those whose initial erosion
SvH scores were less than 5 units. These data support the
importance of early damage as evidence for aggressive
disease.
In the multiple regression model for persistence at 30 months
(data not shown), disease duration for at least 4 months at
inclusion was the single significant prognostic marker. No anti-
body was statistically associated with the outcome of persist-
ence at that time.
Discussion
The main conclusion from our EPA study is that assays target-
ing different citrullinated antigens have distinct prognostic val-
ues for poor outcomes, in addition to their differences in
sensitivity and specificity [20]. When present, anti-Sa antibod-
ies are useful markers of poor prognosis in EPA patients, even
when rapidly treated intensively with conventional DMARDs. In
our EPA population, anti-Sa outperformed anti-CCP antibod-
ies for the prediction of each of the predetermined clinical out-
comes, at least up to 30 months into disease. Despite their
more specific association with RA [20,46], anti-CCP antibod-
ies did not carry any significant advantage over RF. It might
thus be premature to consider replacing RF by anti-CCP anti-
bodies in the clinical evaluation of EPA patients [47]. Differ-
ences between RF and anti-Sa antibodies were also
significant. As a rule, RF proved to be the most sensitive assay
for all outcomes, whereas anti-Sa was the most specific.
At first sight, the lower prevalence of anti-Sa (28% versus
41% for RF) seemed a significant disadvantage. However, the
Table 4
Odds ratio estimates of severe arthritis at 30 months from independent variables present at inclusion
Variable at presentation Odds ratio estimate (95% confidence limits)
Model A Model B Model C
RF ≥ 40 IU/ml 1.788 (0.549–5.825) 2.946 (0.957–9.073) 2.110 (0.715–6.231)
Anti-CCP ≥ 20 U/ml 0.320 (0.075–1.357) 0.917 (0.285–2.953) -
Anti-Sa-positive 8.832 (2.141–36.436)*** - -
Anti-CCP ≥ 60 U/ml - - 1.693 (0.551–5.201)
Age (per year) 1.063 (1.025–1.102)*** 1.049 (1.015–1.084)*** 1.048 (1.014–1.084)***
Male sex 1.741 (0.718–4.223) 1.627 (0.703–3.767) 1.700 (0.733–3.945)
Disease duration 1.686 (0.701–4.058) 1.647 (0.715–3.793) 1.603 (0.700–3.673)
Morning stiffness 0.415 (0.154–1.118) 0.554 (0.218–1.406) 0.502 (0.196–1.284)
Symmetry of arthritis 0.798 (0.174–3.657) 1.085 (0.241–4.880) 1.315 (0.282–6.124)
Swollen joint count 0.985 (0.940–1.033) 0.989 (0.946–1.033) 0.988 (0.945–1.033)
M-HAQ ≥ 1.0 0.666 (0.266–1.666) 0.750 (0.315–1.789) 0.791 (0.330–1.897)
CRP ≥ 8 mg/L 2.594 (0.920–7.312) 2.107 (0.795–5.581) 2.139 (0.807–5.667)
HLA shared epitope 1.096 (0.444–2.704) 0.982 (0.417–2.313) 0.937 (0.401–2.186)
Erosion SvH score 3.472 (1.236–9.575)* 3.751 (1.388–10.135)* 3.611 (1.340–9.729)**
Multivariate regression analysis was performed using all three autoantibodies (model A), without anti-Sa (model B), and without anti-Sa but with a 
higher threshold of 61 U/ml for anti-cyclic citrullinated peptide (anti-CCP) (model C). Confidence limits are 95% Wald confidence limits. Disease 
duration was set as positive when present for at least 4 months. Morning stiffness was set as positive when it lasted for at least 60 min. The 
swollen joint count represents the contribution of each additional joint above the inclusion requirement of three. HLA shared epitope indicates the 
presence of at least one of the HLA DR alleles associated with RA, as listed in the Methods section. Erosion Sharp–van der Heijde (SvH) score 
was set as positive when the value was 5 or more. CRP, C-reactive protein; M-HAQ, modified Health Assessment Questionnaire; RF, rheumatoid 
factor. *P < 0.02; **P < 0.01; ***P < 0.005.
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R600sensitivity of anti-Sa for severe arthritis increased over time in
our cohort, as 29%, 39%, and 45% of all severe patients had
anti-Sa at inclusion, 18 months, and 30 months, respectively.
This observation held true even though anti-Sa positive
patients received as aggressive DMARD treatments as the
other patients with persistent disease. The lack of statistically
significant association of antibodies with persistence was
probably due in part to the dual definition of persistence that
we used, namely the presence of synovitis and/or being
treated. In the absence of a more specific diagnostic test for
persistence, we consider this definition to be the best cur-
rently available in treated recent-onset arthritis. The major lim-
itation with our definition of persistence was the unexpectedly
high (80%) frequency of ongoing use of DMARDs at 30
months. We expect that most patients in protracted remission
will slowly taper their DMARDs over the planned follow-up of
up to 5 years. The confounding influence of prolonged treat-
ment on our definition of persistence should thus progressively
attenuate over these additional 30 months, and the prognostic
value of antibodies for persistence might then become
assessable.
The second important conclusion is that autoantibodies were
present early in only 50 to 60% of the patients who developed
any of the predefined poor outcomes at 30 months. Autoanti-
bodies present early into disease therefore characterize a
large, but limited, subset of EPA patients with poor outcomes.
Detection of autoantibodies in EPA patients must thus be
used in combination with additional variables present at inclu-
sion (for example elevated erosion SvH scores and increasing
age) to best predict, and possibly prevent, the development of
severe disease at 30 months (and beyond).
The third conclusion is that our results should be generally
applicable to EPA patients evaluated by rheumatologists. Sev-
eral reasons support that opinion. First, selection biases were
minimized by the strict exclusion of patients with diseases
known to have a good prognosis (such as crystal-induced
arthritis and monoarthritis) and by a retention rate of 90% at
30 months, without individual missing data. Second, the
patients were thoroughly evaluated with widely available tools
(except for anti-Sa), early in their disease (median 3 months),
and at consistent intervals relative to disease onset. Third, the
predefined severity outcome included both functional disabil-
ity and radiographic damage. Functional impairment and inva-
lidity are the best indicators of severity, but they occur too late
into disease to be useful prognostic indicators. Radiographic
changes, such as those quantified with the SvH score, are
therefore used as surrogates of severity in early disease.
Because disability and radiographic damage are poorly corre-
lated in early arthritis [45,48], both contribute in relatively inde-
pendent ways to the full picture of severity during the first
years of chronic arthritis.
Our observations regarding the prognostic usefulness of anti-
CCP in EPA patients are somewhat at variance with other
reports. The reasons for differences in prognostic value
between anti-CCP and anti-Sa assays therefore merit further
discussion. A first possible explanation relates to deficiencies
of the specific commercial anti-CCP assay used in this paper.
That explanation is unlikely. We observed no significant differ-
ences in sensitivities or specificities between commercial anti-
CCP assays (G. Boire, unpublished observations). Such dif-
ferences would be unlikely, because all commercially available
anti-CCP assays use the same antigen strips [20] and differ
only in technical aspects of the ELISA itself. Thus, the prog-
nostic performance of the particular anti-CCP assay we used
is likely to be generally applicable to commercial anti-CCP
assays.
A second and more likely possibility for the poor performance
of anti-CCP might reside in the design of the assay. The objec-
tives of current anti-CCP assays are to attain the maximal sen-
sitivity for patients with established RA or RA-like disease,
while maintaining a reasonable specificity. This approach
favors a low threshold to report positive results. Because EPA
and RA are very heterogeneous diseases, a more appropriate
design would be to identify subsets of patients with worse out-
comes. In our cohort, most anti-CCP positive sera had high tit-
ers (mean 135.6 U/ml; median 116 U/ml) but, significantly, 11
patients had low or moderate titers (60 U/ml and below). The
presence of low or moderate titers of anti-CCP at inclusion did
not seem to be associated with severe arthritis at 30 months.
Indeed, using a cut-off of 61 U/ml afforded the best OR esti-
mate for the development of severe arthritis, although the pre-
dictive value of this level of anti-CCP was still not statistically
significant (Table 4, model C). It was previously suggested
that many non-RA sera with low anti-CCP titers bind similarly
to citrullinated and non-modified peptides [49]. These sera
would present as false positive anti-CCP results. As a
consequence, we suggest that the threshold for positive
results of commercial anti-CCP assays should be adjusted
upward to increase their prognostic value in EPA patients.
A third explanation for the prognostic discrepancy between
anti-CCP and anti-Sa implies hypothetical qualitative differ-
ences between the anti-Sa and the anti-CCP assays, as sug-
gested by the moderate degree of association between anti-
Sa and anti-CCP results remaining constant across different
cut-offs for positive anti-CCP (phi coefficient 0.6881 for titers
higher than 21 U/ml, and 0.6339 for titers higher than 100 U/
ml). These qualitative differences between assays would
translate into genuine consequent associations with out-
comes. Antibodies present in sera from RA patients recognize
citrullinated peptidic residues in the context of adjoining amino
acid residues and of peptide conformation [19,20]. The short
synthetic peptides used in anti-CCP ELISA were circularized
and covalently bound to plastic strips to circumvent some of
the problems inherent to the use of peptides in solid-phase
Arthritis Research & Therapy    Vol 7 No 3    Boire et al.
R601assays [46]. This design might not be appropriate in very early
polyarthritis, at a time when the immune response to citrulli-
nated antigens is still being matured in vivo by modified
arginine-rich proteins. At present it remains to be confirmed
whether citrullinated proteins in general might perform better
than CCP in ELISA at identifying severe subsets of EPA
patients.
A fourth contributing factor to explain the poor performance of
anti-CCP in our cohort is the influence of aggressive treatment
on EPA prognosis. An earlier time of introduction, a higher
intensity of use, and a more prolonged maintenance of
DMARDs, with the objective of controlling disease, distinguish
our current cohort from previous EPA cohorts established dur-
ing the early 1990s. This more aggressive approach is illus-
trated by the high prevalence of DMARDs still used at 30
months, as well as by the marked decrease in disease activity
over time, as assessed by the DAS28-3, the swollen joint
counts, and the M-HAQ. Possibly because of this relatively
intensive use of DMARDs, more than half of the patients were
in clinical remission at 30 months. According to this hypothe-
sis, the presence of anti-CCP antibodies would indeed identify
patients with a poor natural course, as suggested in previous
EPA or early RA cohorts [25-27,50]. In contrast, anti-CCP
would fail to identify patients who do poorly when exposed rel-
atively early to intensive treatment with current DMARDs.
Such an effect of aggressive treatment was previously
reported to explain the loss of HLA-DR association with sever-
ity in aggressively DMARD-treated patients [51]. If this is true
for anti-CCP, however, patients with anti-Sa would not exhibit
the same generally good response to DMARDs or, alterna-
tively, the association of anti-Sa with severe outcomes would
be so large that the use of DMARDs would not completely
erase it. Because intensive and effective DMARD treatments
capable of slowing the progression of radiological and func-
tional deterioration are increasingly being used in clinical prac-
tice, progressively longer periods of observation in larger
samples of patients should therefore be required to delineate
the true predictive value of potential prognostic markers.
Finally, our data stress the importance of intrinsic aggressive-
ness of arthritis in causing progressive joint damage. At inclu-
sion, 18% of the patients already demonstrated clinically
significant erosive changes. That represents a very early pro-
gression to the pannus phase, and an already missed oppor-
tunity to intervene during the optimal 'therapeutic window' in
these patients. Severe outcomes at 30 months happened
mostly in those patients who already had significant erosive
joint damage at first evaluation. Early erosive changes are
therefore an excellent surrogate marker for an aggressive
arthritis. Whether the use of more sensitive imaging tech-
niques such as ultrasound or magnetic resonance imaging
[52] would increase the sensitivity of detection without affect-
ing its specificity for poor outcomes remains to be defined [52-
54]. In contrast, a serological marker such as anti-Sa antibod-
ies, more highly associated with severe outcomes than RF or
anti-CCP, and present at inclusion in a patient without detect-
able erosions, would probably represent a pre-pannus surro-
gate marker for aggressive arthritis. Such a marker would be
extremely useful in clinical trials and in real-world practice as
well, to select patients for appropriate treatment. In that situa-
tion, additional independent markers (for example inflamma-
tory markers, possibly genetic markers) will still be needed if
we are to attain a more complete prediction of the outcomes
in individual EPA patients.
Conclusion
This study reports the first direct comparison of RF, anti-CCP
and anti-Sa antibodies as prognostic markers in a cohort of
patients with recent-onset inflammatory polyarthritis treated
according to current standards. In this cohort, anti-Sa antibod-
ies were present at inclusion in 45% of the patients who sub-
sequently developed severe outcomes at 30 months. Anti-Sa
antibodies were the single serological marker independently
predictive of poor outcomes and, together with the presence
of joint erosions at inclusion and with increasing age, charac-
terized a subgroup of patients with more rapid and more
severe joint damage. In contrast, anti-CCP antibodies were
not independently associated with severe outcomes in our
patients. Using higher thresholds for positive results slightly
improved the performance of the anti-CCP assay, but the pre-
dictive value of anti-CCP antibodies remained inferior to that
of RF. Although anti-Sa and anti-CCP assays both use citrulli-
nated antigens, our data suggest that the two assays differ in
their ability to predict poor outcomes in patients treated
aggressively early after the onset of inflammatory polyarthritis.
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